Sign in Subscribe
Antigenic determinants

Breakthrough in Atherosclerosis Diagnosis: Triabody-Based Immunoassay Developed

Strategic Insights

— 1 min read

Scientists at Xinjiang University have made a significant discovery in the diagnosis and monitoring of atherosclerosis, a deadly cardiovascular disease. By developing a triabody-based immunoassay, researchers have achieved a precise and sensitive tool for detecting the severity of atherosclerosis and tracking disease progression in patients. This breakthrough could lead to early detection and timely treatment, minimizing the risk of atherosclerotic cardiovascular disease.

Key Takeaways:

  • Researchers developed a triabody-based immunoassay for early diagnosis and monitoring of atherosclerosis.
  • The assay uses a 3136-3155 amino acid sequence (p210) in apolipoprotein B-100 (ApoB100) associated with the severity of atherosclerosis.
  • The triabody displayed single chain fragment variable (scFv) against the p210 peptide in human ApoB100, significantly enhancing its functional affinity and antigen-capturing capability.
  • A rapid and simple method was developed using the triabody for early monitoring of disease progression in clinical settings.
  • The linear range of the sandwich ELISA containing the triabody was 36-576 ng/mL, with a limit of detection of 28.5 ng/mL.
  • The assay was highly sensitive and specific for the pathogenic epitope, with no cross-reactivity with other antigens in serum observed.
  • The triabody-based immunoassay has the potential to detect signals corresponding to the severity of the disease in patients at an early stage of atherosclerosis.

Statistics:

  • The linear range of the sandwich ELISA containing the triabody was 36-576 ng/mL.
  • The limit of detection of the assay was 28.5 ng/mL.
  • The average recovery of intra- and inter-assay were 88.4% +/- 3.0% and 85.5% +/- 5.2%, respectively.
  • The triabody-based immunoassay had 2.5 times higher affinity than that of normal antibody with monomeric scFv.

Sources:

  • Xu, Y., Wang, J., Liu, M., Zahid, R., Hao, J., Zhang, W., & others. (2025). Development of a Triabody-based Immunoassay Against a Pathogenic Epitope In Human Apob100 for the Diagnosis and Monitoring of Atherosclerosis. Microchemical Journal, 218.
  • NewsRx. Studies from Xinjiang University Update Current Data on Atherosclerosis (Development of a Triabody-based Immunoassay Against a Pathogenic Epitope In Human Apob100 for the Diagnosis and Monitoring of Atherosclerosis). World Disease Weekly. November 4, 2025; p 93.

Read more